The Danish company’s controlling shareholder, the Novo Nordisk Foundation, had pushed him to step down after the share price ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

This transition reflects a planned and strategic evolution of MC2 Therapeutics, aligned with the company’s focus on commercial expansion.

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, is honored to share that it was awarded ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing yet." May 22, 2025 Cigna to ...

It is surprising that not even those who use the supercomputer are allowed to know its location. The CEO cites security ...

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the "Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and ...